Yahoo Finance Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024. The transaction was filed on the same day with the SEC.
BioCryst Pharmaceuticals Inc focuses on the development and commercialization of treatments for rare diseases. The company's portfolio includes therapies for hereditary angioedema and other complement-mediated diseases.
The shares were bought at a price of $5.86 per share, totaling $175,800. This purchase follows a trend observed over the past year, where there have been six insider buys and two insider sells within the company.
The stock of BioCryst Pharmaceuticals Inc currently holds a market cap of approximately $1.26 billion. According to the GF Value, the intrinsic value of the stock is estimated at $17.29, suggesting that the shares are undervalued with a price-to-GF-Value ratio of 0.34.
The valuation metrics such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow are considered in the GF Value calculation, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
The insider transaction history and the current stock valuation suggest a cautious approach for potential investors, as indicated by the GF Value status of "Possible Value Trap, Think Twice."
This insider purchase by Helen Thackray could signal confidence in the future prospects of BioCryst Pharmaceuticals Inc, despite the valuation concerns indicated by the GF Value.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
